Skip to main content
OpenTrials
Completed

NCT Number: NCT03124381

A Study to Evaluate the Efficacy and Tolerance of 2 Acne Treatment Regimens on Subjects With Mild to Moderate Acne

This study will compare two different acne treatment regimens for the treatment of acne. Half of participants will receive a cleanser and a light therapy mask, while half of the participants will receive a cleanser, a light therapy topical gel-cream, and a light therapy mask.

Completed

Looking for future studies?

Notify Me

Key information

Age range

12 year–40 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Academic Dermatology Associates, Albuquerque, New Mexico, United States

Loading trial locations.

About this study

Acne vulgaris is a common chronic skin disease involving blockage and/or inflammation of the hair follicles and their accompany sebaceous glands.

Research has shown the benefits of red and blue light therapy in the treatment of mild to moderate acne, with red and blue light shown to target acne-causing bacteria and have an effect on inflammation reduction.

Light-based therapies have been used successfully to treat dermatological conditions since the early 1900s, with various parts of the electromagnetic spectrum (i.e. ultraviolet [UV], visible, near-infrared, etc.) demonstrating different benefits. Light-emitting diodes (LEDs) offer delivery of light to the skin in a gentler manner as compared to light delivered by lasers, primarily due to the lower energy output. It has been reported that LEDs do not deliver enough power to damage tissues and do not have the same risk of accidental eye damage that lasers do. Visible-LED light therapy has been deemed a non-significant risk by the U.S. Food and Drug Administration (FDA) and has been approved for use in humans.

It is well established in the literature that visible light penetration into the epidermal and dermal layers of human skin is primarily governed by absorption and scattering events, with the latter being the more impactful of the two. Visible light penetration into human skin can be increased by reducing scattering. This can be accomplished by temporary hydrogen bonding disruption, which leads to the reversible rearrangement of epidermal and dermal structures that cause scattering. Glycerol (i.e. glycerin) is hypothesized to generate the level of hydrogen bonding disruption described above, and therefore will be investigated in the present study.

This study will look to evaluate and then compare the acne clearing efficacy and tolerance of two different acne treatment regimens - a cleanser used with a currently marketed red and blue light acne light therapy mask alone vs. the cleanser used with the same mask in conjunction with a light therapy topical gel-cream - to determine the efficacy of these treatments and then to assess if the efficacy of the light therapy mask used with the topical gel-cream treatment is non-inferior to the mask alone in the reduction of lesions in mild to moderate acne. If non-inferiority is demonstrated, the mask with topical gel-cream treatment will be further assessed for its superiority to the mask alone.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Has mild to moderate facial acne
  • Has 10-100 blackheads/whiteheads, 10-50 pimples, no cysts, and up to 2 large, hard, painful bumps (nodules)
  • Able to read, write, speak, and understand English
  • In general good health
  • Must agree to practice a medically acceptable form of birth control.
  • Intends to complete the study and willing to follow all study instructions.

Exclusion criteria

  • Very sensitive skin or allergies/sensitivity to skincare products or the test product ingredients.
  • Has a light or photosensitivity disorder or another medical condition that could increase risk to the subject or confuse the study results
  • Is using medication that makes skin more sensitive to light
  • Has severe acne or a pre-existing facial skin condition other than mild to moderate acne
  • has an immune deficiency disorder
  • has been using a product or medication that the stuff investigator determines will increase health risk to the subject or confuse the study results
  • Females that are pregnant, nursing, or planning to become pregnant
  • Males with a female partner who is pregnant or planning to become pregnant
  • Has excessive facial hair
  • Is participating in another study within past 4 weeks
  • Is related to the Sponsor, Investigator, or Study Site

Treatment and study plan

Cleanser, Acne Mask

Device

A facial cleanser will be used twice daily (morning and evening). The light therapy mask will be used for 10 minutes in the evening after washing/drying the face.

Other names: Light Therapy Mask

Cleanser, Gel-Cream, Acne Mask

Device

A facial cleanser will be used twice daily (morning and evening). In the evening after cleansing, the gel-cream will be applied full face and allowed to dry before the light therapy mask is used for 10 minutes.

Other names: Light Therapy Mask, Light Therapy Topical Gel-Cream

Primary outcomes

  1. Global Face Total Lesion Count - Percent Change - Baseline to Week 12

    Time frame: Baseline and Week 12

    Percent change from baseline in global face total lesion count at Week 12

Secondary outcomes

  1. Global Face Total Lesion Count - Percent Change - Baseline to Week 2

    Time frame: Baseline and Week 2

    Percent change from baseline in global face total lesion count at Week 2

  2. Global Face Total Lesion Count - Percent Change - Baseline to Week 4

    Time frame: Baseline and Week 4

    Percent change from baseline in global face total lesion count at Week 4

  3. Global Face Total Lesion Count - Percent Change - Baseline to Week 8

    Time frame: Baseline and Week 8

    Percent change from baseline in global face total lesion count at Week 8

  4. Global Face Total Lesion Count - Percent Change From Baseline to the Mean of All Visits

    Time frame: Baseline to Week 2, Week 4, Week 8, and Week 12

    Global face total lesion counts are averaged across all applicable post-baseline visits (Week 2, Week 4, Week 8, and Week 12). Percent change from baseline to the mean is then calculated.

  5. Global Face Total Lesion Count - Percent Change From Baseline to the Mean of Week 2 and Week 4

    Time frame: Baseline to Week 2 and Week 4

    Global face total lesion counts are averaged across Week 2 and Week 4. Percent change from baseline to the mean is then calculated.

  6. Global Face Total Lesion Count - Percent Change From Baseline to the Mean of Week 4 and Week 8

    Time frame: Baseline to Week 4 and Week 8

    Global face total lesion counts are averaged across Week 4 and Week 8. Percent change from baseline to the mean is then calculated.

  7. Global Face Total Lesion Count - Percent Change From Baseline to the Mean of Week 8 and Week 12

    Time frame: Baseline to Week 8 and Week 12

    Global face total lesion counts are averaged across Week 8 and Week 12. Percent change from baseline to the mean is then calculated.

  8. Global Face Open Comedones Count - Week 2

    Time frame: 2 weeks

    Open comedones count on global face - Week 2

  9. Global Face Open Comedones Count - Week 4

    Time frame: 4 weeks

    Open comedones count on global face - Week 4

  10. Global Face Open Comedones Count - Week 8

    Time frame: 8 weeks

    Open comedones count on global face - Week 8

  11. Global Face Open Comedones Count - Week 12

    Time frame: 12 weeks

    Open comedones count on global face - Week 12

  12. Global Face Closed Comedones Count - Week 2

    Time frame: 2 weeks

    Closed comedones count on global face - Week 2

  13. Global Face Closed Comedones Count - Week 4

    Time frame: 4 weeks

    Closed comedones count on global face - Week 4

  14. Global Face Closed Comedones Count - Week 8

    Time frame: 8 weeks

    Closed comedones count on global face - Week 8

  15. Global Face Closed Comedones Count - Week 12

    Time frame: 12 weeks

    Closed comedones count on global face - Week 12

  16. Global Face Inflammatory Lesion Count - Week 2

    Time frame: 2 weeks

    Papules and pustules counted together

  17. Global Face Inflammatory Lesion Count - Week 4

    Time frame: 4 weeks

    Papules and pustules counted together

  18. Global Face Inflammatory Lesion Count - Week 8

    Time frame: 8 weeks

    Papules and pustules counted together

  19. Global Face Inflammatory Lesion Count - Week 12

    Time frame: 12 weeks

    Papules and pustules counted together

  20. Global Face Non-Inflammatory Lesion Count - Week 2

    Time frame: 2 weeks

    Sum of open comedones and closed comedones

  21. Global Face Non-Inflammatory Lesion Count - Week 4

    Time frame: 4 weeks

    Sum of open comedones and closed comedones

  22. Global Face Non-Inflammatory Lesion Count - Week 8

    Time frame: 8 weeks

    Sum of open comedones and closed comedones

  23. Global Face Non-Inflammatory Lesion Count - Week 12

    Time frame: 12 weeks

    Sum of open comedones and closed comedones

  24. Global Face Total Lesion Count - Week 2

    Time frame: 2 weeks

    Sum of inflammatory and non-inflammatory lesions

  25. Global Face Total Lesion Count - Week 4

    Time frame: 4 weeks

    Sum of inflammatory and non-inflammatory lesions

  26. Global Face Total Lesion Count - Week 8

    Time frame: 8 weeks

    Sum of inflammatory and non-inflammatory lesions

  27. Global Face Total Lesion Count - Week 12

    Time frame: 12 weeks

    Sum of inflammatory and non-inflammatory lesions

  28. Investigator Global Acne Assessment - Week 1

    Time frame: 1 week

    Investigator Global Acne Assessment using Modified Cooke's Scale - Week 1. Modified Cooke's scale ranges from 0 = clear/no acne to 5 = very severe acne. Half-points are allowed.

  29. Investigator Global Acne Assessment - Week 2

    Time frame: 2 weeks

    Investigator Global Acne Assessment using Modified Cooke's Scale - Week 2. Modified Cooke's scale ranges from 0 = clear/no acne to 5 = very severe acne. Half-points are allowed.

  30. Investigator Global Acne Assessment - Week 4

    Time frame: 4 weeks

    Investigator Global Acne Assessment using Modified Cooke's Scale - Week 4. Modified Cooke's scale ranges from 0 = clear/no acne to 5 = very severe acne. Half-points are allowed.

  31. Investigator Global Acne Assessment - Week 8

    Time frame: 8 weeks

    Investigator Global Acne Assessment using Modified Cooke's Scale - Week 8. Modified Cooke's scale ranges from 0 = clear/no acne to 5 = very severe acne. Half-points are allowed.

  32. Investigator Global Acne Assessment - Week 12

    Time frame: 12 weeks

    Investigator Global Acne Assessment using Modified Cooke's Scale - Week 12. Modified Cooke's scale ranges from 0 = clear/no acne to 5 = very severe acne. Half-points are allowed.

  33. Overall Redness of Inflammatory Lesions - Week 1

    Time frame: 1 week

    Additional investigator efficacy assessment. 0-9 scale where 0 = no redness associated with the inflammatory lesions; 9 = overall, inflammatory lesions exhibit severe degree of redness

  34. Overall Redness of Inflammatory Lesions - Week 2

    Time frame: 2 weeks

    Additional investigator efficacy assessment. 0-9 scale where 0 = no redness associated with the inflammatory lesions; 9 = overall, inflammatory lesions exhibit severe degree of redness

  35. Overall Redness of Inflammatory Lesions - Week 4

    Time frame: 4 weeks

    Additional investigator efficacy assessment. 0-9 scale where 0 = no redness associated with the inflammatory lesions; 9 = overall, inflammatory lesions exhibit severe degree of redness

  36. Overall Redness of Inflammatory Lesions - Week 8

    Time frame: 8 weeks

    Additional investigator efficacy assessment. 0-9 scale where 0 = no redness associated with the inflammatory lesions; 9 = overall, inflammatory lesions exhibit severe degree of redness

  37. Overall Redness of Inflammatory Lesions - Week 12

    Time frame: 12 weeks

    Additional investigator efficacy assessment. 0-9 scale where 0 = no redness associated with the inflammatory lesions; 9 = overall, inflammatory lesions exhibit severe degree of redness

  38. Overall Size of Inflammatory Lesions - Week 1

    Time frame: 1 week

    Additional investigator efficacy assessment. 0-9 scale where 0 = no longer visible; 9 = overall size is very large

  39. Overall Size of Inflammatory Lesions - Week 2

    Time frame: 2 weeks

    Additional investigator efficacy assessment. Additional investigator efficacy assessment. 0-9 scale where 0 = no longer visible; 9 = overall size is very large

  40. Overall Size of Inflammatory Lesions - Week 4

    Time frame: 4 weeks

    Additional investigator efficacy assessment. Additional investigator efficacy assessment. 0-9 scale where 0 = no longer visible; 9 = overall size is very large

  41. Overall Size of Inflammatory Lesions - Week 8

    Time frame: 8 weeks

    Additional investigator efficacy assessment. Additional investigator efficacy assessment. 0-9 scale where 0 = no longer visible; 9 = overall size is very large.

  42. Overall Size of Inflammatory Lesions - Week 12

    Time frame: 12 weeks

    Additional investigator efficacy assessment. Additional investigator efficacy assessment. 0-9 scale where 0 = no longer visible; 9 = overall size is very large

Sponsors and collaborators

Lead sponsor

Johnson & Johnson Consumer Inc. (J&JCI)

Industry

Registry information

Official study title

A Multi-Center, Evaluator Blinded, Randomized Clinical Study to Evaluate the Efficacy and Tolerance of Two Acne Treatment Regimens on Subjects With Mild to Moderate Acne Vulgaris

Important dates

Study start
2017
Primary completion
2017
Study completion
2017
First posted
Apr 21, 2017
Registry last updated
Feb 15, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.